In this issue:
Efficacy and safety of dapirolizumab pegol
Enpatoran for active skin manifestations of CLE
Safety profile of IM19 CAR T-cell therapy
Clinical benefits of subcutaneous anifrolumab
Optimal therapeutic range for HCQ
High-dose versus low-dose HCQ
Rate of SLE feature development among incomplete lupus erythematous patients
Antimalarial use and extra-renal damage
Long-term risk of SLE after ANA positivity
Mizoribine for LN
Please login below to download this issue (PDF)